This post was originally published on this site A blood test that examines a panel of 11 specific proteins could help distinguish between benign tumors and malignant ovarian cancer, reducing the need for unnecessary surgeries and leading to an earlier diagnosis, a study shows. Conducted by researchers at Uppsala University and Sahlgrenska Academy at the…
Conditions
Conditions
Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says
This post was originally published on this site Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, an observational study shows. This has been a common concern for metastatic CRPC patients, among whom Xofigo…
World’s First Alport Stamp Is Macedonian Mom’s Latest Win for Rare Disease Patients
This post was originally published on this site It wasn’t until Gordana Loleska’s son David was 14 years old that doctors in their native North Macedonia diagnosed his kidney, vision, and hearing problems as Alport syndrome. Although she had known for years that something was wrong, the news that David would battle a lifelong rare…
Seizures May Reduce Brain Cell Production, Result in Poor Spatial Discrimination, Mouse Study Suggests
This post was originally published on this site Spontaneous seizures reduce the production of new brain cells, and result in poor spatial discrimination — a common occurrence in people with Alzheimer’s disease, according to a mouse study. The study, “Early Seizure Activity Accelerates Depletion of Hippocampal Neural Stem Cells and Impairs Spatial Discrimination in an…
Puma Applies to FDA to Extend Nerlynx’s Use to HER2-Positive Metastatic Breast Cancer
This post was originally published on this site Puma Biotechnology is seeking to extend the use of its breast cancer medicine Nerlynx (neratinib), in combination with capecitabine, to treat women with HER2-positive breast cancer whose disease has spread to other parts of the body, and is metastatic. In a supplemental New Drug Application (sNDA) filed…
Workplace Hazards Account for 30% of Sarcoidosis Cases, Study Suggests
This post was originally published on this site Work-related hazards account for nearly 1 in 3 cases of sarcoidosis, and for at least 1 in 10 cases of other respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis, a new analysis suggests. The analyss, “The Occupational Burden of Nonmalignant Respiratory Diseases. An Official…
FDA Approves Xpovio Combo for Heavily Treated RRMM Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who received at least four prior therapies and failed to respond to treatment. The…
Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC
This post was originally published on this site Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. Similar approvals have previously been granted in the U.S.,…
68Ga-PSMA-11 Better than Axumin at Detecting PC Recurrence, Trial Shows
This post was originally published on this site Among men suspected of having prostate cancer recurrence after surgery, the radiotracer 68Ga-PSMA-11 is better at detecting the cancerous lesions and provides better agreement among experts than the standard Axumin (18F-fluciclovine) tracer, a Phase 2 trial shows. The results were presented at the 2019 Society of Nuclear…
Cancer Vaccine VBI-1901 Well-Tolerated in Recurrent Glioblastoma Patients, Early Phase 1/2a Data Show
This post was originally published on this site Treatment of recurrent glioblastoma with the investigational cancer vaccine VBI-1901 was well-tolerated and associated with stable disease in a subset of patients, according to findings of a Phase 1/2a trial. The study, “Interim results of a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma…
REGN1979 Eliminated Cancer in Most Non-Hodgkin’s Lymphoma Patients in Phase 1 Trial
This post was originally published on this site Regeneron‘s bispecific antibody REGN1979 is showing outstanding clinical effectiveness in B-cell non-Hodgkin’s lymphoma patients who received prior treatments, including those who progressed after CAR T-cell therapies. The treatment completely eliminated the cancer in 71% of follicular lymphoma and 57% of diffuse large B-cell lymphoma patients participated in…
University of Oklahoma Gets $3.75M Grant to Enhance Dementia Care
This post was originally published on this site To enhance care for the growing number of people with Alzheimer’s and other dementia, the U.S. Department of Health and Human Services (HHS) has awarded the University of Oklahoma Health Sciences Center a $3.75 million grant. The grant will establish a partner-reliant program designed to better…